Skip to main content

Compare Stocks

Date Range: 

 Dicerna PharmaceuticalsAxsome TherapeuticsRevance TherapeuticsNGM BiopharmaceuticalsMorphic
SymbolNASDAQ:DRNANASDAQ:AXSMNASDAQ:RVNCNASDAQ:NGMNASDAQ:MORF
Price Information
Current Price$25.11$60.03$27.89$27.98$48.00
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score2.01.61.71.71.5
Analysis Score4.53.43.53.63.5
Community Score3.02.72.63.42.4
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.71.71.7
Earnings & Valuation Score0.60.00.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$42.29$133.83$38.50$39.11$85.00
% Upside from Price Target68.40% upside122.94% upside38.04% upside39.78% upside77.08% upside
Trade Information
Market Cap$1.93 billion$2.26 billion$1.99 billion$2.15 billion$1.74 billion
Beta1.332.591.421.971.01
Average Volume795,762342,411430,277256,673342,508
Sales & Book Value
Annual Revenue$23.90 millionN/A$410,000.00$103.54 million$16.98 million
Price / Sales80.79N/A4,855.7920.81102.37
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.22 per share$5.18 per share$5.00 per share$4.96 per share$4.62 per share
Price / Book11.31N/A5.585.6410.39
Profitability
Net Income$-120,460,000.00$-68,350,000.00$-159,430,000.00$-42,790,000.00$-43,330,000.00
EPS($1.76)($2.01)($3.67)($0.85)($2.69)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-88.81%N/A-5,818.87%-91.64%N/A
Return on Equity (ROE)-71.72%-62.33%-85.72%-29.47%-36.62%
Return on Assets (ROA)-16.60%-47.87%-44.85%-25.58%-20.69%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.36%0.48%N/AN/A
Current Ratio2.62%9.99%7.07%8.01%6.14%
Quick Ratio2.62%9.99%7.01%8.01%6.14%
Ownership Information
Institutional Ownership Percentage80.64%63.64%74.35%49.56%61.49%
Insider Ownership Percentage11.30%26.00%4.80%50.40%39.50%
Miscellaneous
Employees3026047021094
Shares Outstanding76.90 million37.57 million71.38 million77.02 million36.21 million
Next Earnings Date8/5/2021 (Estimated)8/9/2021 (Estimated)8/5/2021 (Estimated)8/11/2021 (Estimated)8/9/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableNot Optionable
SourceHeadline
Morphic (NASDAQ:MORF) Price Target Cut to $102.00 by Analysts at BMO Capital MarketsMorphic (NASDAQ:MORF) Price Target Cut to $102.00 by Analysts at BMO Capital Markets
americanbankingnews.com - May 10 at 9:06 AM
Newsflash: Morphic Holding, Inc. (NASDAQ:MORF) Analysts Have Been Trimming Their Revenue ForecastsNewsflash: Morphic Holding, Inc. (NASDAQ:MORF) Analysts Have Been Trimming Their Revenue Forecasts
finance.yahoo.com - May 5 at 8:10 AM
RBC Capital Stick to Their Buy Rating for Morphic Holding IncRBC Capital Stick to Their Buy Rating for Morphic Holding Inc
investing.com - May 4 at 10:09 AM
Morphic Holding, Inc. (NASDAQ:MORF) Director Sells $523,113.18 in StockMorphic Holding, Inc. (NASDAQ:MORF) Director Sells $523,113.18 in Stock
americanbankingnews.com - May 3 at 5:02 PM
BMO Capital Markets Trims Morphic (NASDAQ:MORF) Target Price to $102.00BMO Capital Markets Trims Morphic (NASDAQ:MORF) Target Price to $102.00
americanbankingnews.com - May 3 at 8:04 AM
Morphic (NASDAQ:MORF) Issues  Earnings Results, Misses Estimates By $0.08 EPSMorphic (NASDAQ:MORF) Issues Earnings Results, Misses Estimates By $0.08 EPS
americanbankingnews.com - April 30 at 3:42 PM
Insider Selling: Morphic Holding, Inc. (NASDAQ:MORF) Director Sells 10,704 Shares of StockInsider Selling: Morphic Holding, Inc. (NASDAQ:MORF) Director Sells 10,704 Shares of Stock
americanbankingnews.com - April 29 at 4:42 PM
Morphic Announces Corporate Highlights and First Quarter 2021 Financial ResultsMorphic Announces Corporate Highlights and First Quarter 2021 Financial Results
finance.yahoo.com - April 29 at 12:50 PM
Morphic Holding, Inc. (MORF) Reports Q1 Loss, Misses Revenue EstimatesMorphic Holding, Inc. (MORF) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - April 29 at 12:50 PM
Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of DirectorsMorphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of Directors
finance.yahoo.com - April 28 at 8:20 PM
Earnings Preview: Morphic Holding, Inc. (MORF) Q1 Earnings Expected to DeclineEarnings Preview: Morphic Holding, Inc. (MORF) Q1 Earnings Expected to Decline
finance.yahoo.com - April 28 at 3:13 PM
Is Morphic Holding, Inc. (NASDAQ:MORF) Popular Amongst Insiders?Is Morphic Holding, Inc. (NASDAQ:MORF) Popular Amongst Insiders?
finance.yahoo.com - April 27 at 1:48 PM
Insider Selling: Morphic Holding, Inc. (NASDAQ:MORF) Director Sells 5,146 Shares of StockInsider Selling: Morphic Holding, Inc. (NASDAQ:MORF) Director Sells 5,146 Shares of Stock
americanbankingnews.com - April 27 at 10:52 AM
Morphic Holding, Inc. (NASDAQ:MORF) Director Fund V. Gp L.P. Omega Sells 19,787 SharesMorphic Holding, Inc. (NASDAQ:MORF) Director Fund V. Gp L.P. Omega Sells 19,787 Shares
americanbankingnews.com - April 23 at 7:16 PM
Insider Selling: Morphic Holding, Inc. (NASDAQ:MORF) Director Sells 8,081 Shares of StockInsider Selling: Morphic Holding, Inc. (NASDAQ:MORF) Director Sells 8,081 Shares of Stock
americanbankingnews.com - April 21 at 1:26 PM
Is Morphic Holding a Buy?Is Morphic Holding a Buy?
finance.yahoo.com - April 14 at 9:39 AM
Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American ...Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American ...
apnews.com - April 12 at 12:46 PM
Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual MeetingMorphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 12 at 12:46 PM
THE REVENGE OF SHERLOCK HOLMES! To Embark on UK Spiegel Tent Tour - Broadway WorldTHE REVENGE OF SHERLOCK HOLMES! To Embark on UK Spiegel Tent Tour - Broadway World
broadwayworld.com - April 2 at 7:44 PM
Morphic Holding Inc (MORF) CFO and COO Marc Schegerin Bought $190,500 of SharesMorphic Holding Inc (MORF) CFO and COO Marc Schegerin Bought $190,500 of Shares
finance.yahoo.com - March 11 at 7:43 AM
Independent Director Vikas Goyal Just Bought A Handful Of Shares In Morphic Holding, Inc. (NASDAQ:MORF)Independent Director Vikas Goyal Just Bought A Handful Of Shares In Morphic Holding, Inc. (NASDAQ:MORF)
nasdaq.com - March 9 at 1:25 PM
MORF Stock Price: $103 Target (Up From $40) By Wells FargoMORF Stock Price: $103 Target (Up From $40) By Wells Fargo
pulse2.com - March 7 at 7:21 AM
Morphic price target raised at Wells Fargo on positive data in inflammatory bowel diseaseMorphic price target raised at Wells Fargo on positive data in inflammatory bowel disease
seekingalpha.com - March 3 at 1:22 PM
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public OfferingMorphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering
finance.yahoo.com - March 3 at 12:38 AM
Why Morphic Holding Stock Is Falling TodayWhy Morphic Holding Stock Is Falling Today
finance.yahoo.com - March 2 at 2:34 PM
DateCompanyBrokerageAction
4/22/2021Dicerna PharmaceuticalsThe Goldman Sachs GroupInitiated Coverage
4/19/2021Dicerna PharmaceuticalsTruist SecuritiesBoost Price Target
4/13/2021Dicerna PharmaceuticalsSVB LeerinkLower Price Target
3/8/2021Dicerna PharmaceuticalsChardan CapitalBoost Price Target
3/8/2021Dicerna PharmaceuticalsHC WainwrightBoost Price Target
3/1/2021Dicerna PharmaceuticalsB. RileyBoost Price Target
5/12/2020Dicerna PharmaceuticalsRoyal Bank of CanadaInitiated Coverage
5/11/2020Dicerna PharmaceuticalsSunTrust BanksBoost Price Target
5/12/2021Axsome TherapeuticsBTIG ResearchReiterated Rating
3/8/2021Axsome TherapeuticsMorgan StanleyBoost Price Target
3/2/2021Axsome TherapeuticsMizuhoLower Price Target
1/8/2021Axsome TherapeuticsJefferies Financial GroupInitiated Coverage
12/31/2020Axsome TherapeuticsUBS GroupReiterated Rating
12/3/2020Axsome TherapeuticsCantor FitzgeraldBoost Price Target
10/1/2020Axsome TherapeuticsWilliam BlairReiterated Rating
9/29/2020Axsome TherapeuticsBank of AmericaInitiated Coverage
4/28/2020Axsome TherapeuticsGuggenheimBoost Price Target
4/27/2020Axsome TherapeuticsLADENBURG THALM/SH SHBoost Price Target
4/14/2021Revance TherapeuticsNeedham & Company LLCReiterated Rating
10/26/2020Revance TherapeuticsBarclaysBoost Price Target
4/16/2020Revance TherapeuticsStifel NicolausLower Price Target
2/25/2020Revance TherapeuticsPiper SandlerBoost Price Target
3/11/2021NGM BiopharmaceuticalsRaymond JamesBoost Price Target
12/21/2020NGM BiopharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/21/2020NGM BiopharmaceuticalsSmith Barney CitigroupBoost Price Target
6/4/2020NGM BiopharmaceuticalsBMO Capital MarketsInitiated Coverage
3/23/2020NGM BiopharmaceuticalsCowenReiterated Rating
3/1/2021MorphicWells Fargo & CompanyBoost Price Target
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.